Fabišíková Katarína, Hamidová Olívia, Behulová Regína Lohajová, Závodná Katarína, Priščáková Petra, Repiská Vanda
Faculty of Medicine, Institute of Medical Biology, Genetics and Clinical Genetics, Comenius University, Bratislava, Slovakia.
Department of Clinical Genetics, St. Elizabeth Cancer Institute, Bratislava, Slovakia.
Front Genet. 2020 Dec 15;11:590486. doi: 10.3389/fgene.2020.590486. eCollection 2020.
-associated polyposis (MAP) is a rare hereditary condition caused by the biallelic mutation in the gene encoding MUTYH glycosylase. This enzyme is a key member of the base excision repair (BER) pathway responsible for the repair of DNA lesions formed by reactive oxygen species (ROS). We report two cases of MAP. In case 1, a 67-year-old woman who presented with a personal history of colorectal and endometrial cancer and a family history of cancer syndromes underwent multigene panel testing that revealed a germline homozygous (biallelic) pathogenic variant c.1187G > A (p.Gly396Asp) in the gene. Subsequent sequencing analysis performed in the offspring of the proband identified all three asymptomatic offspring as carriers of this pathogenic variant. In case 2, a 40-year-old woman with a strong family history of colorectal cancer [the proband's sister was a carrier of the pathogenic variant c.536A > G (p.Tyr179Cys) of the gene] and renal cancer underwent sequencing analysis of the gene. The pathogenic heterozygous (monoallelic) variant c.536A > G (p.Tyr179Cys) of the gene was identified in the proband. We found another pathogenic variant of the gene-heterozygous (monoallelic) mutation c.1187G > A (p.Gly396Asp) in the genome of the proband's husband. Molecular analysis of their offspring revealed that they are compound heterozygotes for pathogenic variants c.536A > G (p.Tyr179Cys)/c.1187G > A (p.Gly396Asp). This paper shows the importance of genetic testing of asymptomatic relatives of the proband to ensure an early surveillance and management of individuals positive for pathogenic variant (s) in the gene.
MUTYH相关息肉病(MAP)是一种罕见的遗传性疾病,由编码MUTYH糖基化酶的基因双等位基因突变引起。这种酶是碱基切除修复(BER)途径的关键成员,负责修复由活性氧(ROS)形成的DNA损伤。我们报告了两例MAP病例。病例1中,一名67岁女性,有结直肠癌和子宫内膜癌个人史以及癌症综合征家族史,接受了多基因检测,结果显示该基因存在种系纯合(双等位基因)致病性变异c.1187G>A(p.Gly396Asp)。随后在先证者的后代中进行的测序分析确定所有三名无症状后代均为该致病性变异的携带者。病例2中,一名40岁女性,有结直肠癌(先证者的姐姐是该基因致病性变异c.536A>G(p.Tyr179Cys)的携带者)和肾癌家族史,接受了该基因的测序分析。在先证者中鉴定出该基因的致病性杂合(单等位基因)变异c.536A>G(p.Tyr179Cys)。我们在先证者丈夫的基因组中发现了该基因的另一个致病性变异——杂合(单等位基因)突变c.1187G>A(p.Gly-396Asp)。对他们后代的分子分析显示,他们是该基因致病性变异c.536A>G(p.Tyr179Cys)/c.1187G>A(p.Gly396Asp)的复合杂合子。本文显示了对先证者无症状亲属进行基因检测对于确保对该基因致病性变异阳性个体进行早期监测和管理的重要性。